...
首页> 外文期刊>Bulletin of Clinical Psychopharmacology >The effects of pharmachotherapy on serum folic acid and vitamin B12 levels in patients with schizophrenia, bipolar disorder and major depressive disorder
【24h】

The effects of pharmachotherapy on serum folic acid and vitamin B12 levels in patients with schizophrenia, bipolar disorder and major depressive disorder

机译:药物治疗对精神分裂症,躁郁症和重度抑郁症患者血清叶酸和维生素B12水平的影响

获取原文

摘要

Objective: Folic acid and vitamin B12 are essential cofactors in several biochemical pathways that are critical for neurobiological and hematological functions. Vitamin B12 and folate deficiencies are reported in schizophrenia and depression patients but there are only a few studies investigating the effects of the treatment on serum folic acid and vitamin B12 levels. This study aimed to investigate serum folic acid and vitamin B12 levels in patients with depression, schizophrenia and bipolar disorder and the effects of the drug treatment on these vitamin levels. Method: Twenty-six schizophrenia, 16 major depressive, and 47 bipolar (manic, depressive or mixed episode) disorder inpatients diagnosed according to DSM-IV criteria and 21 healthy controls were included in the study. Serum vitamin B12 and folic acid levels were measured before the treatment. The patients received the treatment at therapeutic doses for 5 weeks. Fifteen of the schizophrenic patients were treated with atypical antipsychotics including risperidone, olanzapine, quetiapine and 11 of them with typical antipsychotics (haloperidol or zuclopenthicsole). Bipolar patients received mood stabilizer and antipsychotic and/or antidepressant according to their present episode. The patients with major depressive disorder were treated with various antidepressant drugs. Serum vitamin B12 and folic acid levels were measured again in all patients after five weeks. The same measurements were performed only once in the controls. Results: Serum folic acid and vitamin B12 levels were not significantly different among the patient groups and the controls in pre-treatment. In schizophrenic patients, serum folic acid levels were significantly reduced after typical antipsychotic treatment compared to those in pretreatment and to those of the controls while they did not change after atypical antipsychotic treatment. Bipolar patients who received lithium had lower serum folic acid levels in post-treatment than in pre-treatment. There was a negative correlation between serum folic acid levels and severity of depression in the patients with major depressive disorder. Conclusion: The results of the study suggest that serum folic acid and vitamin B12 values in schizophrenia, bipolar disorder, and major depressive disorder did not differ from healthy controls. However, it seems that some drug treatments might lead to a decrease in folic acid levels. Nevertheless, further studies are needed to confirm the effects of specific drug treatments on these vitamins.
机译:目的:叶酸和维生素B12是多种生化途径中必不可少的辅因子,对神经生物学和血液学功能至关重要。精神分裂症和抑郁症患者中维生素B12和叶酸缺乏症的报道,但仅有少数研究调查了该治疗对血清叶酸和维生素B12水平的影响。这项研究旨在调查抑郁症,精神分裂症和躁郁症患者的血清叶酸和维生素B12水平,以及药物治疗对这些维生素水平的影响。方法:研究纳入根据DSM-IV标准诊断的26例精神分裂症,16例重度抑郁症和47例双相情感障碍(躁狂,抑郁或混合发作)住院患者和21名健康对照者。治疗前测量血清维生素B12和叶酸水平。患者接受了治疗剂量的治疗,持续了5周。 15例精神分裂症患者接受了非典型抗精神病药物治疗,包括利培酮,奥氮平,喹硫平,其中11例患有典型抗精神病药物(氟哌啶醇或zuclopenthicsole)。双相情感障碍患者根据其当前发作情况接受了情绪稳定剂和抗精神病药和/或抗抑郁药。重度抑郁症患者接受了各种抗抑郁药治疗。五周后再次测量所有患者的血清维生素B12和叶酸水平。在对照中仅进行一次相同的测量。结果:在治疗前的患者组和对照组之间,血清叶酸和维生素B12的水平没有显着差异。在精神分裂症患者中,与常规治疗和对照组相比,典型抗精神病药物治疗后血清叶酸水平显着降低,而在非典型抗精神病药物治疗后血清叶酸水平没有变化。接受锂治疗的双相患者在治疗后的血清叶酸水平低于治疗前的水平。重度抑郁症患者的血清叶酸水平与抑郁严重程度之间呈负相关。结论:研究结果表明,精神分裂症,双相情感障碍和重度抑郁症患者的血清叶酸和维生素B12值与健康对照组无差异。但是,似乎某些药物治疗可能导致叶酸水平降低。然而,需要进一步的研究来确认特定药物治疗对这些维生素的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号